Subscribe
istock-504614468_brauns
brauns / iStockphoto.com
10 January 2019Americas

Gilead announces licence and collaboration deal with Yuhan

Gilead Sciences, a biopharmaceutical company based in the US, has entered into a licensing and collaboration agreement with South Korean healthcare company Yuhan.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
German patent court publishes reasoning in Gilead SPC dispute
6 November 2018   Germany’s Federal Patent Court has published the reasoning behind its decision to revoke Gilead Sciences’ supplementary protection certificate for HIV/AIDS treatment Truvada,
Americas
Gilead signs immuno-oncology deal with Tango
2 November 2018   California-based Gilead Sciences has signed a collaboration agreement with Tango Therapeutics to discover and develop a pipeline of immuno-oncology treatments for cancer patients.
Asia-Pacific
South Korean global licensing spikes n 2018
22 January 2019   South Korean pharmaceutical companies entered into 11 out-licensing deals with overseas partners in 2018, according to the country’s Ministry of Health and Welfare.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Big Pharma
German patent court publishes reasoning in Gilead SPC dispute
6 November 2018   Germany’s Federal Patent Court has published the reasoning behind its decision to revoke Gilead Sciences’ supplementary protection certificate for HIV/AIDS treatment Truvada,
Americas
Gilead signs immuno-oncology deal with Tango
2 November 2018   California-based Gilead Sciences has signed a collaboration agreement with Tango Therapeutics to discover and develop a pipeline of immuno-oncology treatments for cancer patients.
Asia-Pacific
South Korean global licensing spikes n 2018
22 January 2019   South Korean pharmaceutical companies entered into 11 out-licensing deals with overseas partners in 2018, according to the country’s Ministry of Health and Welfare.

More on this story

Big Pharma
German patent court publishes reasoning in Gilead SPC dispute
6 November 2018   Germany’s Federal Patent Court has published the reasoning behind its decision to revoke Gilead Sciences’ supplementary protection certificate for HIV/AIDS treatment Truvada,
Americas
Gilead signs immuno-oncology deal with Tango
2 November 2018   California-based Gilead Sciences has signed a collaboration agreement with Tango Therapeutics to discover and develop a pipeline of immuno-oncology treatments for cancer patients.
Asia-Pacific
South Korean global licensing spikes n 2018
22 January 2019   South Korean pharmaceutical companies entered into 11 out-licensing deals with overseas partners in 2018, according to the country’s Ministry of Health and Welfare.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility